Figures & data
Figure 1. Polymorphonuclear leukocyte counts. Symbols and abbreviations: Δ patients; ○ healthy control subjects;
![Figure 1. Polymorphonuclear leukocyte counts. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.](/cms/asset/74fd494a-a13c-4cd8-b5fa-2916ac90df19/ihyt_a_956810_f0001_b.jpg)
Figure 2. Lymphocyte subsets. Symbols and abbreviations: Δ patients; ○ healthy control subjects;
![Figure 2. Lymphocyte subsets. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.](/cms/asset/e2b3c339-d099-4eb5-b5f6-6748a25fe906/ihyt_a_956810_f0002_b.jpg)
Table 1. Effects of hyperthermia on polymorphonuclear leucocytes and lymphocyte subsets (q-values).
Figure 3. TLR-4, IL-10 and HSPB1 gene expression. Symbols and abbreviations: Δ patients; ○ healthy control subjects;
![Figure 3. TLR-4, IL-10 and HSPB1 gene expression. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.](/cms/asset/5d67bace-8168-488e-9ea8-fa13faa86f2d/ihyt_a_956810_f0003_b.jpg)
Table 2. Effects of hyperthermia treatment on TLR-4, IL-10 and HSPB1 gene expression (q-values).
Figure 4. Systemic cytokines. Symbols and abbreviations: Δ patients; ○ healthy control subjects;
![Figure 4. Systemic cytokines. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.](/cms/asset/7ef20f4d-6282-4b99-8120-2364ee65e468/ihyt_a_956810_f0004_b.jpg)
Table 3. Effects of hyperthermia treatment on plasma cytokine concentrations (q-values).
Figure 5. Acute phase reactants. Symbols and abbreviations: Δ patients; ○ healthy control subjects;
![Figure 5. Acute phase reactants. Symbols and abbreviations: Δ patients; ○ healthy control subjects; Display full size, total duration of hyperthermia treatment including active heating and heat retention period; bef, baseline measurements immediately before start of hyperthermia treatment around 7:00 a.m.; 0, end of active heating period (achievement of target body core temperature); 1, 1 h after end of active heating (end of heat retention period); 2, 2 h after end of active heating; 3, 3 h after end of active heating; 24, 24 h after end of active heating.](/cms/asset/e21e7b8d-e607-48c0-9b77-99f1d07e39c6/ihyt_a_956810_f0005_b.jpg)
Table 4. Effects of hyperthermia treatment on acute phase reactants (q-values).